Original title: Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. Reference: Laura Mauri et al. N Engl J Med 2014;371:2155-66. Dual antiplatelet therapy is recommended after a drug-eluting stent to prevent thrombotic complications. The clinical benefit of this scheme it is not clear beyond one year. Patients were registered to receive a...
Original title: Three-Year Outcomes After Revascularization With Everolimus-and Sirulimus -Eluting Stents From the SORT OUT IV Trial. Reference: Lisette Okkels Jensen et al. J Am CollCardiolIntv, 2014;7: 840-8. Drug eluting stents (DES) have been shown to safely and effectively reduce restenosis compared to bare-metal stents. While the risk of thrombosis remains a matter of concern when it comes...
Original: Direct drug-eluting Stenting to reduce stent reestenosis (STRESSED). Reference: Wouter S. Remkes et al. J Am Coll Cardiol Intv, 2014;7: 751-8. Direct stenting, without predilation, has been considered a safe and effective technique that reduces procedural time, radiation exposure, contrast material and costs; however, the pertinent studies tested conventional stents only. This study aimed at assessing whether...
Original title: Dedicated two-stents technique in complex bifurcation percutaneous coronary intervention with use of everolimus-eluting stents: The EES-bifurction study. Reference: Nisharamed I. Kherada, et al. International Journal of Cardiology 2014;174:13-17 Bifurcation PCI, especially 1.1.1 Medina bifurcation lesions PCI, is particularly challenging and has been associated with increased restenosis. The use of drug eluting stents (DES) associated to...
Original title: Sirolimius-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stents restenosis: Results from the ISAR-DESIRE 2 trial. Reference: Sebastian Kufner, et al. Cardiovascular Revascularization Medicine 2014, 15:69-75. DES restenosis has always generated a challenge and a puzzle when defining the strategy of revascularization by angioplasty: A quite used concept was to switch to...
Original title: Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following Resolute zotarolimus-eluting stent implantation. Reference: Silber S, Kirtane AJ, Belardi JA, et al. Eur Heart J. 2014; Epub ahead of print. Dual antiplatelet aggregation optimal time after implantation of a new generation drug-eluting stent (DES) is still discussed. This...
Original title: Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomized, single-blind, multicentre, non-inferiority trial. Reference: Von Birgelen C et al. The Lancet. 2014; Epub ahead of print. In the 3rd generation zotarolimus-eluting stent, platform was modified to increase flexibility and make implant easier in complex lesions. This study was...
Original title: Incidences, Predictors, and Clinical Outcomes of Acute and Late Stent Malapposition Detected by Optical Coherence Tomography After Drug-Eluting Stent Implantation Reference: Im E. et al. CircCardiovascInterv. 2014 Jan 14. [Epubahead of print] This paper analyzed the imaging of 351 patients by optical coherence tomography (OCT) who received drug-eluting stents over 356 lesions between 2009 and...
Original title: A Randomized Comparison of Drug-Eluting Balloon Versus Everolimus-Eluting Stent in Patients With Bare-Metal Stent In-Stent Restenosis: The RIBS V Clinical Trial. Reference: Fernando Alfonso et al. J Am Coll Cardiol. 2014; Epub ahead of print. Drug-eluting stents (DES) have proven to be superior in terms of restenosis than bare metal stents (BMS). BMS, however due...
Original title: Everolimus-eluting stents in patients undergoing percutaneous coronary Intervention: Final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial. Reference: Sorin J. Brener et al. Am Heart J 2013;0:1-8. The XIENCE stent (Abbott Vascular, Santa Clara, CA) is...